{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:08:50Z","timestamp":1793066930043,"version":"4.5.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7,15]]},"DOI":"10.1093\/infdis\/jix211","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T15:09:48Z","timestamp":1493392188000},"page":"228-236","source":"Crossref","is-referenced-by-count":94,"title":["White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs"],"prefix":"10.1093","volume":"216","author":[{"given":"Helen W","family":"Boucher","sequence":"first","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center and Tufts University School of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Schenectady, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H F","family":"Chambers","sequence":"additional","affiliation":[{"name":"University of California at San Francisco;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H","family":"Ebright","sequence":"additional","affiliation":[{"name":"Rutgers University, Piscataway, New Jersey;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Jezek","sequence":"additional","affiliation":[{"name":"Infectious Diseases Society of America, Arlington, Virginia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara E","family":"Murray","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Texas Medical School at Houston;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason G","family":"Newland","sequence":"additional","affiliation":[{"name":"St Louis Children\u2019s Hospital, Missouri;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Ostrowsky","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H","family":"Rex","sequence":"additional","affiliation":[{"name":"CARB-X, Boston, Massachusetts;"},{"name":"F2G, Manchester, and"},{"name":"Expert-in-Residence, Wellcome Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Infectious Diseases Society of America","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,5,5]]},"reference":[{"key":"key\n\t\t\t\t20180306115534_CIT0001","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0002","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/cid\/civ723","article-title":"Optimal usage of colistin: are we any closer?","volume":"61","author":"Pogue","year":"2015","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0003","article-title":"Identification of a novel plasmid-mediated colistin-resistance gene, mcr-2, in Escherichia coli, Belgium, June 2016","volume":"21:1\u20136","author":"Xavier","year":"2016","journal-title":"Euro Surveill"},{"key":"key\n\t\t\t\t20180306115534_CIT0004","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1128\/AAC.01103-16","article-title":"Escherichia coli harboring mcr-1 and blaCTX-M on a novel IncF plasmid: first report of mcr-1 in the United States","volume":"60","author":"McGann","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0005","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.2016.9690","article-title":"Infectious disease expert sees threat from colistin-resistant superbug","volume":"316","author":"Abbasi","year":"2016","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180306115534_CIT0006","doi-asserted-by":"crossref","first-page":"812","DOI":"10.7326\/M16-2079","article-title":"The United Nations and the urgent need for coordinated global action in the fight against antimicrobial resistance","volume":"165","author":"Boucher","year":"2016","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180306115534_CIT0007","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0008","year":"2014"},{"key":"key\n\t\t\t\t20180306115534_CIT0009","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/clpt.2014.116","article-title":"Antibacterial drug development: challenges, recent developments, and future considerations","volume":"96","author":"Nambiar","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180306115534_CIT0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/cis688","article-title":"White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens","volume":"55","author":"Spellberg","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0011","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0012","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1473-3099(12)70293-1","article-title":"A comprehensive regulatory framework to address the unmet need for new antibacterial treatments","volume":"13","author":"Rex","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0013","doi-asserted-by":"crossref","first-page":"S139","DOI":"10.1093\/cid\/cit578","article-title":"Better tests, better care: improved diagnostics for infectious diseases","volume":"57","author":"Caliendo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0014","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0015","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20180306115534_CIT0016","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"Streptomycin treatment of pulmonary tuberculosis: a medical research council investigation","volume":"2","author":"Streptomycin in Tuberculosis Trials Committee","year":"1948","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20180306115534_CIT0017","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.2214\/ajr.183.6.01831539","article-title":"Randomized controlled trials","volume":"183","author":"Stolberg","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"key\n\t\t\t\t20180306115534_CIT0018","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1128\/IAI.00908-10","article-title":"Reproducible science","volume":"78","author":"Casadevall","year":"2010","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20180306115534_CIT0019","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0009-9236(03)00018-3","article-title":"Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval","volume":"73","author":"Peck","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180306115534_CIT0020","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0021","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.02624-12","article-title":"Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia","volume":"57","author":"Louie","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0022","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-016-2053-x","article-title":"Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients","volume":"72","author":"Mattioli","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180306115534_CIT0023","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1128\/AAC.01330-10","article-title":"Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia","volume":"55","author":"Lodise","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0026","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1172\/JCI200316814","article-title":"Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy","volume":"112","author":"Jumbe","year":"2003","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180306115534_CIT0027","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: critical interactions of \u2018bug and drug\u2019","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"key\n\t\t\t\t20180306115534_CIT0028","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1086\/430611","article-title":"Bacterial-population responses to drug-selective pressure: examination of garenoxacin\u2019s effect on Pseudomonas aeruginosa","volume":"192","author":"Tam","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0029","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1128\/AAC.00461-13","article-title":"Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model","volume":"57","author":"Vanscoy","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0030","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1128\/AAC.42.9.2375","article-title":"In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations","volume":"42","author":"Andes","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0031","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1128\/AAC.45.1.13-22.2001","article-title":"Use of preclinical data for selection of a phase II\/III dose for evernimicin and identification of a preclinical MIC breakpoint","volume":"45","author":"Drusano","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0032","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.49.9.3944-3947.2005","article-title":"Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem","volume":"49","author":"Bhavnani","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0033","doi-asserted-by":"crossref","first-page":"4351","DOI":"10.1128\/AAC.00251-07","article-title":"Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model","volume":"51","author":"Ambrose","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0034","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1086\/591427","article-title":"Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design","volume":"47","author":"Ambrose","year":"2008","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0035","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1086\/653057","article-title":"Pharmacokinetic-pharmacodynamic considerations in the design of hospital-acquired or ventilator-associated bacterial pneumonia studies: look before you leap!","volume":"51","author":"Ambrose","year":"2010","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0036","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0732-8893(95)00053-D","article-title":"Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins","volume":"22","author":"Craig","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0037","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1128\/AAC.46.6.1665-1670.2002","article-title":"Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0038","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1128\/AAC.00961-16","article-title":"Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis","volume":"60","author":"Srivastava","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0039","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1469-0691.2005.01265.x","article-title":"Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations","volume":"11","author":"Andes","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20180306115534_CIT0040","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1128\/AAC.00144-09","article-title":"Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole","volume":"53","author":"Rodvold","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180306115534_CIT0041","year":"2015"},{"key":"key\n\t\t\t\t20180306115534_CIT0042","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0043","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1093\/cid\/cis688","article-title":"White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens","volume":"55","author":"Infectious Diseases Society of America","year":"2012","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0044","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"},{"key":"key\n\t\t\t\t20180306115534_CIT0046","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0047","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/cid\/ciw244","article-title":"Efficient delivery of investigational antibacterial agents via Sustainable Clinical Trial Networks","volume":"63","author":"McDonnell","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20180306115534_CIT0048","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1086\/678592","article-title":"Guidance for the knowledge and skills required for antimicrobial stewardship leaders","volume":"35","author":"Cosgrove","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"key":"key\n\t\t\t\t20180306115534_CIT0049","year":"2016"},{"key":"key\n\t\t\t\t20180306115534_CIT0050","year":"2016"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/216\/2\/228\/24263956\/jix211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T07:08:31Z","timestamp":1569136111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/216\/2\/228\/3798533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,5]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,5,5]]},"published-print":{"date-parts":[[2017,7,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix211","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,7,15]]},"published":{"date-parts":[[2017,5,5]]}}}